Continuous glucose monitoring-based time-in-range using insulin glargine 300 units/ml versus insulin degludec 100 units/ml in type 1 diabetes: The head-to-head randomized controlled InRange trial.
Tadej BattelinoThomas DanneSteve V EdelmanPratik ChoudharyPr Eric RenardJukka WesterbackaBhaswati MukherjeeValerie PilorgetMathieu CoudertRichard M BergenstalPublished in: Diabetes, obesity & metabolism (2022)
Using clinically relevant CGM metrics, InRange shows that Gla-300 is non-inferior to IDeg-100 in people with T1D, with comparable hypoglycaemia and safety profiles.